A key element of the U.S. Food and Drug Administration’s (FDA’s) mission is focused on helping to ensure that all products the agency regulates, which includes drugs available to consumers, are of high quality and safe.
Ensuring greater accountability in our nation’s drug supply chain is major part of these efforts.
Towards that end, the agency has launched a new pilot project in which participants representing the drug supply chain (e.g., manufacturers, repackagers and other stakeholders) can pilot the use of innovative and emerging approaches for enhanced tracing and verification of prescription drugs in the U.S. to ensure suspect and illegitimate products do not enter the supply chain.
FDA Seeking Participants for Track-and-Trace Pilot Projects
The FDA is seeking eligible entities to apply to participate in the program.
The pilot will inform the development of the enhanced electronic, interoperable track-and-trace system for industry set to go into effect in 2023 as part of the Drug Supply Chain Security Act, using technologies that may become part of our enhanced expectations for reliable track-and-trace systems.
(The US FDA for short, has announced the launch of an open blockchain pilot program. Scott Gottlieb Commissioner of the FDA decided to use the technology specifically for tracking the provenance of pharmaceuticals. Courtesy of Bloxlive and YouTube. Posted on Feb 13, 2019.)